Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  33.00 0.44% 7,592.00 7,566.00 7,568.00 7,588.00 7,503.00 7,533.00 4,310,174 16:35:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 18,386.4 1,167.2 77.7 100.9 99,600

Merck, AstraZeneca Get FDA Priority Review for Selumetinib in NF1

14/11/2019 12:55pm

Dow Jones News

Astrazeneca (LSE:AZN)
Historical Stock Chart

From Jan 2019 to Jan 2021

Click Here for more Astrazeneca Charts.

By Colin Kellaher


Merck & Co. (MRK) and AstraZeneca PLC (AZN) Thursday said the U.S. Food and Drug Administration accepted and granted priority review to their new-drug application for selumetinib in the rare and incurable genetic condition neurofibromatosis type 1, or NF1.

The drug makers said the NDA covers selumetinib as a potential new medicine for children ages three years and older with NF1 and symptomatic, inoperable plexiform neurofibromas.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period to six months from the standard 10 months. Merck and AstraZeneca said the agency set a target action date for the second quarter of 2020.

AstraZeneca and Merck in 2017 formed a collaboration to develop and commercialize certain oncology products, including selumetinib.


Write to Colin Kellaher at


(END) Dow Jones Newswires

November 14, 2019 07:40 ET (12:40 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210115 17:47:39